Search results
In trial over cancer claims, pharma executive questioned about proper storage, handling of Zantac
Chicago Sun-Times· 10 hours agoThe attorneys representing a woman suing the drug makers behind Zantac continued to make the case...
Innate Pharma (IPHA) to Release Earnings on Tuesday
ETF DAILY NEWS· 2 days agoInnate Pharma (NASDAQ:IPHA – Get Free Report) is scheduled to post its quarterly earnings results before the market opens on Tuesday, May 14th. Individual interested in registering ...
Verona Pharma plc (NASDAQ:VRNA) Q1 2024 Earnings Call Transcript
Insider Monkey via Yahoo Finance· 5 days agoVerona Pharma plc (NASDAQ:VRNA) Q1 2024 Earnings Call Transcript May 9, 2024 Verona Pharma plc isn’t...
Nuvectis Pharma, Inc. Expected to Post Q2 2024 Earnings of ($0.23) Per Share (NASDAQ:NVCT)
ETF DAILY NEWS· 5 days agoNuvectis Pharma, Inc. (NASDAQ:NVCT – Free Report) – Analysts at Roth Capital increased their Q2 2024 EPS estimates for shares of Nuvectis Pharma in a research ...
Royalty Pharma (RPRX) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
Zacks via Yahoo Finance· 6 days agoThe headline numbers for Royalty Pharma (RPRX) give insight into how the company performed in the...
HOOKIPA Pharma First Quarter 2024 Earnings: Beats Expectations
Simply Wall St. via Yahoo Finance· 4 days agoHOOKIPA Pharma (NASDAQ:HOOK) First Quarter 2024 Results Key Financial Results Revenue: US$36.6m (up...
UPDATE 2-US FDA extends review of Ascendis Pharma's hormone disorder therapy
Reuters via Yahoo Finance· 14 hours agoThe U.S. Food & Drug Administration has extended its review of Ascendis Pharma's therapy to treat adult patients with a hormone disorder by three months, the company said ...
Royalty Pharma pays startup $525M for stake in Sanofi MS drug
BioPharma Dive via Yahoo Finance· 6 days agoThe deal gives the company milestone payments and royalties to a medicine, frexalimab, that Sanofi...
Sumitomo Pharma Announces FDA Acceptance of Supplemental New Drug Application for Vibegron in Men...
WKRN Nashville· 2 days agoSumitomo Pharma America, Inc. (SMPA), announced today the U.S. Food and Drug Administration (FDA) has accepted its supplemental New Drug Application (sNDA) for vibegron (GEMTESA ...
Ocuphire Pharma First Quarter 2024 Earnings: Misses Expectations
Simply Wall St. via Yahoo Finance· 3 days agoOcuphire Pharma (NASDAQ:OCUP) First Quarter 2024 Results Key Financial Results Revenue: US$1.71m...
